Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the best dose and side effects of avelumab when given together
with azacitidine and to see how well they work in treating patients with acute myeloid
leukemia that is not responding to treatment or has come back. Monoclonal antibodies, such as
avelumab, may interfere with the ability of cancer cells to grow and spread. Azacitidine may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving avelumab and azacitidine may work better in treating patients with acute myeloid
leukemia.